Sneha Shah Jain, MD
Internal Medicine · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Jain’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$7,881
Medicare paid this office $7,881 for 196 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $2,046 | $71 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 150 | $1,171 | $7 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 15 | $364 | $23 |
Who their Medicare patients are
196 Original Medicare patients in 2024. Average age 75 · Under 65 9% · 85 and older 18% · Women 52% · Also on Medicaid 30% · Health risk score 1.93. Above the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 75% · Coronary heart disease 49% · Heart failure 48% · Atrial fibrillation 47% · Diabetes 41% · Chronic kidney disease 38% · Depression 23% · Stroke 23% · Cancer 20% · COPD 17% · Dementia 11%.
The office billed $40,025, Medicare allowed $9,893 and paid $7,881; for 246 services of 14 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Medicaid work
$709 in 2024
Medicaid paid $709 for 46 billed services this clinician did in 2024, up to 44 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 46 | $709 |
| 2024 | 46 | 1 | 44 | $709 |
Drugs they prescribed that Part D paid
$34,581
Pharmacies billed $34,581 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 160) in 2024. At or below the middle of the specialty; the typical internal medicine clinician is at 1%.
131 generic and 29 brand-name prescriptions · $34,581 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ezetimibe | 15 | $911 | $61 |
| Rosuvastatin | 13 | $548 | $42 |
| Metoprolol | 11 | $131 | $12 |
| Atorvastatin | 31 | $106 | $3 |
| Amlodipine Besylate | 11 | $45 | $4 |
See all 6 drugs
| Ezetimibe | 15 | $911 | $61 |
| Rosuvastatin | 13 | $548 | $42 |
| Metoprolol | 11 | $131 | $12 |
| Atorvastatin | 31 | $106 | $3 |
| Amlodipine Besylate | 11 | $45 | $4 |
| Carvedilol | 11 | $43 | $4 |
Year by year
| 2024 | 160 | 51 | 0% (0) | 18% | $34,581 |
| 2023 | 104 | 28 | 0% (0) | 18% | $21,953 |
| 2022 | 56 | 21 | 0% (0) | 30% | $13,555 |
| 2021 | 297 | 55 | 0% (0) | None | $25,978 |
| 2020 | 583 | 77 | 0% (0) | None | $37,944 |
| 2019 | 694 | 62 | 0% (0) | None | $38,919 |
| 2018 | 173 | 24 | 0% (0) | 13% | $7,631 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Entresto | 12 | $13,752 | $1,146 |
| Rosuvastatin | 14 | $260 | $19 |
| Atorvastatin | 22 | $257 | $12 |
| Metoprolol | 13 | $43 | $3 |
2021: 6 drugs
| Atorvastatin | 19 | $870 | $46 |
| Metoprolol | 15 | $485 | $32 |
| Losartan | 13 | $467 | $36 |
| Amlodipine Besylate | 26 | $213 | $8 |
| Omeprazole | 14 | $186 | $13 |
| Diclofenac | 16 | $183 | $11 |
2020: 13 drugs
| Diclofenac | 32 | $1,384 | $43 |
| Gabapentin | 15 | $661 | $44 |
| Atorvastatin | 59 | $524 | $9 |
| Levothyroxine | 17 | $363 | $21 |
| Amlodipine Besylate | 59 | $324 | $5 |
| Famotidine | 17 | $318 | $19 |
| Rosuvastatin | 16 | $297 | $19 |
| Carvedilol | 21 | $243 | $12 |
| Escitalopram | 12 | $174 | $15 |
| Losartan | 19 | $142 | $7 |
| Metformin | 33 | $118 | $4 |
| Lisinopril | 18 | $56 | $3 |
| Hydrochlorothiazide | 17 | $45 | $3 |
2019: 21 drugs
| Incruse Ellipta | 20 | $7,374 | $369 |
| Diclofenac | 24 | $1,417 | $59 |
| Atorvastatin | 79 | $893 | $11 |
| Mirtazapine | 16 | $527 | $33 |
| Bupropion Xl | 11 | $419 | $38 |
| Levothyroxine | 24 | $340 | $14 |
| Chlorthalidone | 16 | $307 | $19 |
| Carvedilol | 36 | $303 | $8 |
| Nifedipine Er | 13 | $283 | $22 |
| Pravastatin | 17 | $256 | $15 |
| Gabapentin | 17 | $231 | $14 |
| Ranitidine | 15 | $188 | $13 |
| Amlodipine Besylate | 39 | $166 | $4 |
| Metformin | 43 | $165 | $4 |
| Fluticasone Propionate | 13 | $138 | $11 |
| Lisinopril | 29 | $130 | $4 |
| Losartan | 12 | $87 | $7 |
| Losartan-Hydrochlorothiazide | 12 | $85 | $7 |
| Furosemide | 18 | $83 | $5 |
| Sertraline | 11 | $72 | $7 |
| Hydrochlorothiazide | 14 | $47 | $3 |
2018: 4 drugs
| Atorvastatin | 24 | $205 | $9 |
| Gabapentin | 11 | $163 | $15 |
| Metformin | 12 | $43 | $4 |
| Lisinopril | 12 | $25 | $2 |
Money from drug and device companies
$7,023 in 2025
| 2025 | 3 | 10 | $6,840 | $7,023 |
| 2024 | 2 | 5 | $3,420 | $3,452 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| E.R. Squibb & Sons L.L.C. | None | $6,840 | 7 payments
|
| Janssen Research & Development | None | $160 | 2 payments
|
| Esperion Therapeutics | Nexletol | $23 | 1 payment
|
See all 10 published payments
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-06-11 | None | $950 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-06-10 | None | $950 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-06-02 | None | $380 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-05-30 | None | $380 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-05-21 | None | $950 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-05-21 | None | $1,140 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-05-20 | None | $2,090 |
| Esperion Therapeutics | Meals · 2025-03-31 | Nexletol | $23 |
| Janssen Research & Development | Meals · 2025-03-28 | None | $100 |
| Janssen Research & Development | Meals · 2025-03-28 | None | $60 |
See earlier years (2024)
2024: $3,452
| E.R. Squibb & Sons L.L.C. | Camzyos | $3,420 | 4 payments
|
| Abbott Laboratories | Ensite | $32 | 1 payment
|
Professional record
- NPI
- 1952725145
- Trained
- Johns Hopkins University School of Medicine, 2018
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Cardiology (207RC0000X); Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2014-02-10
- NPI last updated
- 2024-10-18
- NPI record certified
- 2024-10-18
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 622 W 168th St # 205, New York, NY, 10032